John Smyth, MD, of the University of Edinburgh, discusses oncology from an international point of view.
James L. Mulshine, MD, of Rush University Medical Center, and David E. Gerber, MD, of The University of Texas Southwestern Medical Center, discuss the ALCHEMIST trial, an NCI initiative to address the role of molecular testing and targeted therapies for earlier-stage lung disease (Abstract TPS7583).
Andrew James Martin, PhD, of NHMRC Clinical Trials Centre, University of Sydney, discusses a form of vitamin B3 that reduced the incidence of new nonmelanoma skin cancers in high-risk patients (Abstract 9000).
James O. Armitage, MD, of the University of Nebraska Medical Center, and Tony Mok, MD, of The Chinese University of Hong Kong, discuss oncology from an international point of view.
Claus Garbe, MD, of the University of Tuebingen, and Anthony J. Olszanski, RPh, MD, of Fox Chase Cancer Center, discuss the survival of sentinel lymph node-positive melanoma patients with and without complete lymph node dissection (Abstract LBA9002).
Jedd Wolchok, MD, PhD, of Memorial Sloan Kettering Cancer Center discusses therapies for treatment-naive patients with advanced melanoma (Abstract LBA1).
